Common genetic variants in proinflammatory and other immunoregulatory genes and risk for non-Hodgkin lymphoma.
Profound disruption of immune function is an established risk factor for non-Hodgkin lymphoma. We report here a large-scale evaluation of common genetic variants in immune genes and their role in lymphoma. We genotyped 57 single nucleotide polymorphisms (SNP) from 36 candidate immune genes in 1,172 non-Hodgkin lymphoma cases and 982 population-based controls from a US multicenter study. We calculated odds ratios (OR) and 95% confidence intervals (95% CI) for the association between individual SNP and haplotypes with non-Hodgkin lymphoma overall and five well-defined subtypes. A haplotype comprising SNPs in two proinflammatory cytokines, tumor necrosis factor-alpha and lymphotoxin-alpha (rs1800629, rs361525, rs1799724, rs909253, and rs2239704), increased non-Hodgkin lymphoma risk overall (OR, 1.31; 95% CI, 1.06-1.63; P = 0.01) and notably for diffuse large B cell (OR, 1.64; 95% CI, 1.23-2.19; P = 0.0007). A functional nonsynonymous SNP in the innate immune gene Fc gamma receptor 2A (FCGR2A; rs1801274) was also associated with non-Hodgkin lymphoma; AG and AA genotypes were associated with a 1.26-fold (95% CI, 1.01-1.56) and 1.41-fold (95% CI, 1.10-1.81) increased risk, respectively (P(trend) = 0.006). Among non-Hodgkin lymphoma subtypes, the association with FCGR2A was pronounced for follicular and small lymphocytic lymphomas. In conclusion, common variants in genes influencing proinflammatory and innate immune responses were associated with non-Hodgkin lymphoma risk overall and their effects could vary by subtype. Our results require replication but potentially provide important clues for investigating common genetic variants as susceptibility factors and in disease outcomes, treatment responses, and immunotherapy targets.
Wang
Sophia S
SS
Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Rockville, MD 20892-7234, USA. wangso@mail.nih.gov
Cerhan
James R
JR
Hartge
Patricia
P
Davis
Scott
S
Cozen
Wendy
W
Severson
Richard K
RK
Chatterjee
Nilanjan
N
Yeager
Meredith
M
Chanock
Stephen J
SJ
Rothman
Nathaniel
N
D000328:Adult; D000368:Aged; D005189:False Positive Reactions; D005260:Female; D005802:Genes, MHC Class II; D005838:Genotype; D006239:Haplotypes / Q000235:genetics; D006801:Humans; D007249:Inflammation / Q000235:genetics*; D008228:Lymphoma, Non-Hodgkin / Q000145:classification / Q000453:epidemiology* / Q000235:genetics; D008233:Lymphotoxin-alpha / Q000235:genetics; D008297:Male; D008875:Middle Aged; D020641:Polymorphism, Single Nucleotide; D017452:Receptors, IgG / Q000235:genetics; D018426:SEER Program / Q000706:statistics & numerical data; D014409:Tumor Necrosis Factor-alpha / Q000235:genetics; D014481:United States / Q000453:epidemiology
C445323:FCGR2A protein, human; D008233:Lymphotoxin-alpha; D017452:Receptors, IgG; D014409:Tumor Necrosis Factor-alpha